Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2020-09-17 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - "DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)" OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug by the U.S. FDA. It is a short announcement (2553 characters) and does not contain financial data, regulatory certifications, or detailed report content. It is not an annual report, earnings release, or any detailed financial or governance report. The content focuses on a product development update and clinical trial approval, which is a typical corporate announcement. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-09-17 English
NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF 2020 INTERIM REPORT
Report Publication Announcement Classification · 95% confidence The document is a notification letter dated 18 September 2020 from CSPC Pharmaceutical Group Limited informing non-registered shareholders about the publication of the company's 2020 Interim Report. It provides instructions on how to request a printed copy of the report and future corporate communications. The document does not contain the actual interim report or any financial data but serves as a notice of the report's availability on the company's and the stock exchange's websites. The document length is 6842 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA) because it announces the availability of the interim report without including the report itself.
2020-09-17 English
INTERIM REPORT 2020
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial data, including condensed consolidated financial statements such as profit and loss, comprehensive income, financial position, changes in equity, and cash flows. It also includes management discussion and analysis, financial highlights for the six months ended 30 June 2020, and notes to the condensed consolidated financial statements. The presence of interim financial statements and analysis for a half-year period clearly indicates this is a comprehensive financial report for a period shorter than a full fiscal year. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-09-17 English
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG "ALMB-0168" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a new investigational drug ALMB-0168 in China. It is a short announcement (2789 characters) and does not contain any financial data, financial statements, or detailed report content. It is not an annual or interim report, earnings release, or any form of regulatory filing with financial results. The document is an announcement of a significant corporate development related to drug development and clinical trial approval. It does not fit into categories like M&A, capital update, or management changes. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2020-09-15 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share-related transactions for the month ended 31/08/2020. The content focuses on share capital changes and confirmations related to securities issued, with no financial performance data or earnings information. This type of document is a regulatory filing related to share capital movements and confirmations, typical for compliance with stock exchange rules. It does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update, but aligns with Regulatory Filings (RNS) as a general compliance document reporting share capital movements and confirmations to the exchange.
2020-09-01 English
CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF STEAM SUPPLY AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the renewal of a steam supply agreement between CSPC XNW (a subsidiary of CSPC Pharmaceutical Group Limited) and Hebei Hongyuan. It discusses connected transactions under Chapter 14A of the Hong Kong Listing Rules, including details about the agreement terms, pricing, historical transaction amounts, proposed annual cap, and implications under the Listing Rules. The document is structured as a formal announcement to shareholders and the market about continuing connected transactions and compliance with regulatory requirements. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is not a management or governance report, nor a call transcript or legal proceeding update. The content fits the category of a Regulatory Filing (RNS) because it is a regulatory announcement about connected transactions and compliance with listing rules, which is a common type of regulatory disclosure in Hong Kong. The document length (15,000 characters) and detailed content confirm it is a full announcement, not a brief notice or report publication announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-08-28 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.